Xenetic Biosciences Inc
XBIO
NASDAQ
Biotechnology
$3.28
USD
-0.01 (-0.30%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $7.56M
Volume 6.7K
Revenue
$1.47M
TTM
-60.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-2.48M
TTM
+19.7%
YoY
Operating Cash Flow
$-2.31M
TTM
+8.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.6 | 0.0 | 0.0 | 0.8 | 0.7 |
YoY Growth | -18.8% | — | -100.0% | +36.0% | +12.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.6 | 0.0 | 0.0 | 0.8 | 0.7 |
Selling, General & Administrative | 0.7 | 0.8 | 0.6 | 0.6 | 1.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 1.3 | 1.6 | 1.4 | 1.3 | 1.6 |
Operating Income | -0.7 | -1.6 | -1.4 | -0.5 | -1.0 |
EBITDA | -0.7 | -1.6 | -1.4 | -0.5 | -1.0 |
Other Income / Expense | 0.0 | 1.0 | 0.8 | -0.0 | -0.0 |
Total Other Income / Expense | 0.0 | 1.1 | 0.8 | 0.0 | 0.0 |
Income Before Income Taxes | -0.7 | -0.5 | -0.6 | -0.5 | -0.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -0.7 | -0.5 | -0.6 | -0.5 | -0.9 |
Consolidated Net Income / Loss | -0.7 | -0.5 | -0.6 | -0.5 | -0.9 |
Net Income Attributable to Common Shareholders | -0.7 | -0.5 | -0.6 | -0.5 | -0.9 |
Basic EPS | -$0.45 | -$0.33 | -$0.27 | -$0.20 | -$0.41 |
Diluted EPS | -$0.45 | -$0.33 | -$0.27 | -$0.20 | -$0.41 |
Basic Shares Outstanding | 1.5M | 1.5M | 2.2M | 2.3M | 2.3M |
Diluted Shares Outstanding | 1.5M | 1.5M | 2.2M | 2.3M | 2.3M |